Showing 1591-1600 of 2150 results for "".
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T
- Influx of New Contact Lens Patients Calls for Simplified Wear-and-Care Educationhttps://modernod.com/news/influx-of-new-contact-lens-patients-calls-for-simplified-wear-and-care-education/2478671/Within days of mask guidelines being implemented earlier this year, the reports of fogging started streaming in from glasses and sunglasses wearers. Social feeds were soon packed with photos of the annoying condensation and news reports began offering tips on how to avoid condensation. In 2020, t
- Biden Builds Out Health Team with Xavier Becerra Named to Lead HHShttps://modernod.com/news/biden-builds-out-health-team-with-xavier-becerra-named-to-lead-hhs/2478635/US President-elect Joe Biden released more of his health team picks on Monday, nominating California Attorney General Xavier Becerra to serve as Secretary of Health and Human Services (HHS). In addition, Vivek Murthy, who was the US Surgeon General from 2014 to 2017, has been selected to return t
- UK Government Asks Regulator to Clear “Temporary Supply” of AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/uk-government-asks-regulator-to-clear-temporary-supply-of-astrazenecas-covid-19-vaccine/2478594/The UK government on Friday said that it formally asked the Medicines and Healthcare products Regulatory Agency (MHRA) to assess the suitability of AstraZeneca’s COVID-19 vaccine candidate AZD1222 for “temporary supply.” Health and Social Care Secretary Matt Hancock noted that t
- CureVac to Move COVID-19 Vaccine Into Late-Stage Testing on Positive Early Datahttps://modernod.com/news/curevac-to-move-covid-19-vaccine-into-late-stage-testing-on-positive-early-data/2478489/CureVac reported interim phase 1 study data on Monday showing that its experimental COVID-19 vaccine triggered strong binding and neutralizing antibody responses, and also gave a “first indication” that T-cells had been activated in a cohort of healthy adult volunteers. The company sa
- Study of Lilly’s COVID-19 Antibody LY-CoV555 Paused Over Potential Safety Issuehttps://modernod.com/news/study-of-lillys-covid-19-antibody-ly-cov555-paused-over-potential-safety-issue/2478416/A phase 3 trial of Eli Lilly’s investigational monoclonal antibody LY-CoV555 for the treatment of COVID-19 has been temporarily suspended out of an “abundance of caution” because of a “potential safety concern,” according to emails that government officials sent on T
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t
- TearClear Raises $22M in Series B Fundinghttps://modernod.com/news/tearclear-raises-22m-in-series-b-funding/2478158/TearClear announced it has raised $22 million in a Series B funding round. The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications. Led by Chief Executive Officer Robert Dempsey, T
- Proposed Medicare Physician Fee Schedule Rule Jeopardizes Patient Care, Argues the Surgical Care Coalitionhttps://modernod.com/news/proposed-medicare-physician-fee-schedule-rule-jeopardizes-patient-care-argues-the-surgical-care-coalition/2478115/The Medicare Physician Fee Schedule proposed rule released by the Centers for Medicare & Medicaid Services (CMS) for 2021 jeopardizes patient care, specifically surgical care, according to a Surgical Care Coalition news release. While the proposed rule takes steps to increase access to care t